Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Risks
Competitive Advantages
Established Biosimilar Market Presence: Coherus has a track record of commercial success with UDENYCA (pegfilgrastim biosimilar), which has captured a significant market share, and CIMERLI (ranibizumab biosimilar), providing a stable revenue base and recognized market access in key therapeutic areas.
Strong Regulatory Expertise: The company has successfully navigated the complex FDA approval process for multiple biosimilar products, demonstrating robust regulatory capabilities essential for bringing biologics to market.
Specialized Commercial Infrastructure: Coherus possesses an established commercial team and infrastructure focused on oncology and inflammatory diseases, enabling efficient launch and penetration of new and existing biosimilar and oncology products.
Risks
Intensifying Biosimilar Competition: The market for Coherus's key biosimilar products, such as Udenyca, is highly competitive with existing and new entrants potentially eroding market share and pricing power.
Loqtorzi Market Adoption Challenges: The successful commercialization and broad market penetration of its new oncology product, Loqtorzi, depends on physician acceptance, patient access, and favorable reimbursement policies, which may not materialize as expected.
Regulatory Approval and Development Delays: Obtaining and maintaining regulatory approvals for its products and pipeline candidates, including new indications or additional biosimilars, is a complex and lengthy process subject to potential delays or rejection by health authorities.
Today
6:38 PM
Over a week ago
Jun 23, 2:03 PM
May 11, 4:42 PM
May 11, 7:08 AM
May 11, 6:11 AM
Mar 9, 4:36 PM
Feb 13, 5:45 AM
Feb 12, 4:07 PM
Jan 22, 4:10 PM
Jan 22, 4:08 PM
Jan 5, 9:46 AM
Dec 8, 8:42 AM
Nov 13, 5:33 PM
Nov 7, 9:19 AM
Nov 6, 5:21 PM
Sep 4, 7:34 AM
Aug 7, 4:55 PM
No more stories
